Company intelligence / Profile preview
Nitrase Therapeutics
Brisbane, California, United Statesnitrasetx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Nitrase Therapeutics has developed NDC-0524, a first-in-class monoclonal antibody with high selectivity for nitrated alpha-synuclein (nSyn), which is expected to begin a randomized Phase 1/2a trial in Q4 2025. Preclinical data from multiple studies demonstrate that their antibody prevents pathological spread of Parkinson's disease.
- Therapeutic areas
- OncologyImmunologyRare DiseasesNeurology
- Modalities
- AntibodiesSmall molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
HitGen
Beyond the preview
Go deeper on Nitrase Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nitrase Therapeutics.